

iBio, Inc.: Consumption, Demand, Sales, Competitor and Forecast 2016 – 2021

iBio, Inc. Global Market 2016 Analysis and Forecast to 2021

PUNE, INDIA, September 26, 2016

/EINPresswire.com/ -- The report provides comprehensive information on the therapeutics under development by [iBio, Inc.](#), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Complete Report @

<https://www.wiseguyreports.com/reports/64976-5-ibio-inc-product-pipeline-review-2016>

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of iBio, Inc.
- The report provides overview of iBio, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product



description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses iBio, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features iBio, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Get Sample Report @ <https://www.wiseguyreports.com/sample-request/649765-ibio-inc-product-pipeline-review-2016>

Reasons to buy

- Evaluate iBio, Inc.'s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for iBio, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding iBio, Inc.'s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Have any query @ <https://www.wiseguyreports.com/enquiry/649765-ibio-inc-product-pipeline-review-2016>

Table of Content

Key Information 6

Key Facts 6

iBio, Inc. - Research and Development Overview 7

Key Therapeutic Areas 7

iBio, Inc. - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Pipeline Products - Combination Treatment Modalities 12

iBio, Inc. - Pipeline Products Glance 13

iBio, Inc. - Clinical Stage Pipeline Products 13

Phase I Products/Combination Treatment Modalities 13
iBio, Inc. - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Discovery Products/Combination Treatment Modalities 15
iBio, Inc. - Drug Profiles 16
anthrax vaccine 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
HAI-05 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
influenza [strain A/H1N1] vaccine 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
malaria vaccine 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
NaAPR1M-74 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
anthrax + plague vaccine 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
human papillomavirus [Serotype 16] vaccine 23
Product Description 23
Mechanism of Action 23
R&D Progress 23

Buy now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=649765 □

Continued...

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)☐

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/346496293>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.